Vitamin B12 Supplement to Prevent Cognitive Decline
Primary Purpose
Cognitive Decline
Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Vitamin B12
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Cognitive Decline
Eligibility Criteria
Inclusion Criteria:
- >/= 70 years old
- B12: 150 - 300 pmol/L
- Caregiver (personal contact at least once a week)
Exclusion Criteria:
- Dementia
- Peripheral neuropathy
- Anaemia (Hb<10 g/dl)
- Renal failure (creatinine > 150 µmol/L
- Stroke
Sites / Locations
- The Chinese University of Hong Kong
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Vitamin B12
Placebo
Arm Description
Vitamin B12, 1mg, daily, 27 months
Placebo comparator
Outcomes
Primary Outcome Measures
Change in Clinical Dementia Rating Scale (CDR)
Secondary Outcome Measures
Change in Neurocognitive test battery (NTB) score
NTB including tests of executive funciton, psychomotor speed and memory
Change in serum homocysteine (µmol/L)
Full Information
NCT ID
NCT02457507
First Posted
May 22, 2015
Last Updated
January 26, 2016
Sponsor
Chinese University of Hong Kong
1. Study Identification
Unique Protocol Identification Number
NCT02457507
Brief Title
Vitamin B12 Supplement to Prevent Cognitive Decline
Study Type
Interventional
2. Study Status
Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
August 2011 (undefined)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
January 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese University of Hong Kong
4. Oversight
5. Study Description
Brief Summary
Background: Older diabetic people are at greater risk of cognitive decline than non-diabetic people. Vitamin B12 deficiency in older people is associated with cognitive impairment and Alzheimer's disease. Vitamin B12 deficiency may therefore contribute to cognitive decline in older diabetic people.
Objective: To determine whether the correction of mild vitamin B12 deficiency in cognitively normal older diabetic people reduces the incidence of cognitive decline.
Design: randomized, double blind, placebo controlled trial Subject: Cognitively normal diabetic outpatients aged 70 years or older with plasma vitamin B12 150-300 pmol/L in medical and family medicine/ general outpatient clinics.
Procedure: After excluding those with clinical manifestations of vitamin B12 deficiency and without family member who can reliably inform on cognitive functioning (personal contact at least once a week), eligible patients will be invited to participate in this clinical trial. After obtaining written consent, research assistant (RA) will record demographic and clinical information from the subjects and perform neuropsychological tests - 1. Clinical dementia rating scale (CDR), 2. neurocognitive test battery (see below) 3. Chinese Mini mental state examination (MMSE), 4. Geriatric depression scale (GDS). Fasting blood will be taken for serum methylmalonic acid (MMA). Those with cognitive impairment and significant comorbidities will be excluded.
264 eligible subjects will be randomly assigned to take either two Vitamin B12 500 microgram or two identical looking placebo tablets once daily for 27 months.
All subjects or family caregivers are reviewed in the research clinic every 12 weeks in which the research assistant performs a pill count and dispenses the trial tablets. At 9 monthly intervals, the subjects will have neurocognitive test battery repeated at research clinic. CDR will be repeated at month 18 and 27. At month 9 and 27, fasting serum MMA and vitamin B12 will be repeated.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cognitive Decline
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
271 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vitamin B12
Arm Type
Experimental
Arm Description
Vitamin B12, 1mg, daily, 27 months
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin B12
Intervention Description
2 tablets
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
2 tablets
Primary Outcome Measure Information:
Title
Change in Clinical Dementia Rating Scale (CDR)
Time Frame
Change from baseline in CDR at month 9, 18, 27
Secondary Outcome Measure Information:
Title
Change in Neurocognitive test battery (NTB) score
Description
NTB including tests of executive funciton, psychomotor speed and memory
Time Frame
Change from baseline in NTB score at month 9, 18, 27
Title
Change in serum homocysteine (µmol/L)
Time Frame
Change from baseline in serum homocysteine at month 9, 27
10. Eligibility
Sex
All
Minimum Age & Unit of Time
70 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
>/= 70 years old
B12: 150 - 300 pmol/L
Caregiver (personal contact at least once a week)
Exclusion Criteria:
Dementia
Peripheral neuropathy
Anaemia (Hb<10 g/dl)
Renal failure (creatinine > 150 µmol/L
Stroke
Facility Information:
Facility Name
The Chinese University of Hong Kong
City
Hong Kong
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
27823800
Citation
Kwok T, Lee J, Ma RC, Wong SY, Kung K, Lam A, Ho CS, Lee V, Harrison J, Lam L. A randomized placebo controlled trial of vitamin B12 supplementation to prevent cognitive decline in older diabetic people with borderline low serum vitamin B12. Clin Nutr. 2017 Dec;36(6):1509-1515. doi: 10.1016/j.clnu.2016.10.018. Epub 2016 Oct 27.
Results Reference
derived
Learn more about this trial
Vitamin B12 Supplement to Prevent Cognitive Decline
We'll reach out to this number within 24 hrs